Erik MacLaren PhD

About Erik MacLaren PhD

Erik MacLaren, PhD has published work including research briefs, medical news articles, literature reviews, and opinion leader interviews that have appeared in Targeted Oncology and IASLC Lung Cancer News. He has written about a variety of endocrinologyrelated topics including thyroid cancer, ovarian cancer , and type 2 diabetes. Erik’s familiarity and experience mining medical literature allows him to produce accurate, highquality articles.

Dr. MacLaren earned a doctorate in pharmacology from the University of Colorado Health Sciences Center and has 9 years of experience as a researcher in cellular and molecular neuroscience at institutions in the US, UK, and Canada. He started his freelance medical writing business in 2013 and has worked primarily on projects directed at a professional audience.

Articles Written by Erik MacLaren PhD

Combination Therapy, Exenatide and Pioglitazon, Effective Alternative to Insulin in Type 2 Diabetes

Multiplatform Molecular Testing May Reduce Unnecessary Thyroidectomies

Benefits of Testosterone Supplementation Elusive in TTrials

Testosterone Offers Modest Gains for Anemia and Bone Density

Non-Invasive Imaging May Reduce Need for Removal of Benign Thyroid Nodules

Gestational Diabetes Increases Macrovascular Risk

New ADA Guidelines for Diabetic Neuropathy

Address Psychosocial Status to Assure Best Outcomes in Diabetes Care, Says ADA

Pioglitazone Reduces Both Diabetes and Cardiovascular Events

Optimal Therapy to Prolong Normoglycemia Remission Proposed

Financial Disclosures for Erik MacLaren PhD

EndocrineWeb, a Remedy Health Media, LLC website, is committed to ensuring that the medical information it presents is accurate, balanced, objective, and trustworthy.

To help achieve this goal, EndocrineWeb requires all authors, editors, and reviewers to disclose any financial relationships or affiliations they have with companies whose products or services may be mentioned in the content they author, edit, or review.

The intent of this policy is to identify any perceived, potential, or real conflicts of interest so that readers can make their own judgments about the value of information being presented.

This author has not disclosed any relationships